About us

With over 33 years of distinguished service at Boston Consulting Group (BCG), primarily within the biopharma and medtech sectors, Philippe Guy has built deep global expertise, working across Europe (London, Paris, Zurich), Japan, and the United States (New York and Miami). In addition to serving clients across the entire value chain and advising on major transactions, he played a pivotal role in developing BCG’s Healthcare Practice Area in these regions. His leadership extended to steering the Global Healthcare Practice for nine years, further amplifying his impact on the industry. He was also peer-selected to represent all sector and functional practices on BCG’s global Executive Committee, reflecting his broad strategic vision and leadership.
Philippe Guy is engaged on a pro bono basis with the Fondation de la Mer, where he focuses on scaling its international impact. This includes contributing to key United Nations negotiations (including at UNOC 3 in Nice, recently) and facilitating the formation of a coalition of like-minded European foundations: the Alliance for European Seas.
In addition to his role at MedinCell, Philippe also serves on the board of Moleac, a Singapore-based company supporting patients with brain injuries and neurological conditions.
Philippe Guy’s multifaceted career reflects a blend of operational and strategic leadership in healthcare, a constant focus on value creation and sustainable transformation, and a deep-seated commitment to every aspect of ESG.

Tone Kvåle is the CFO of Herantis Pharma, and she has more than 25 years of experience from the biotech and life sciences industry. She was CFO at Nordic Nanovector, a publicly listed company in Norway, for 7 years, and prior to that, she held CFO roles at NorDiag (publicly listed company), Kavli Holding, Dynal Biotech, as well as senior management positions at Invitrogen/Life Technologies, in US, now part of Thermo Fisher. In these roles, she helped raise over EUR 200m in financing, was involved in IPO’s and M&A’s and was responsible for financial reporting under various reporting standards including US GAAP and IFRS. She has been board director and chair of the audit committee of Bonesupport AB (BONEX), Sweden from December 2016 until May 2022. Tone has a diploma in finance and administration from UiT, The Arctic University of Norway, Harstad. She has completed the prescribed course of study and the examination for Advanced Programme in Corporate Finance at The Norwegian School of Economics, NHH in 2022.

Pascal Touchon has 40 years of international experience in the biopharmaceutical industry, holding both operational and strategic leadership positions and serving on the boards of American and European companies. Throughout his career Pascal has been focused on transforming the lives of patients with serious medical conditions through pioneering science, teamwork, and a commitment to excellence. He is the former Global Head of Strategy and Business Development, as well as the Global Head of the Cell & Gene division at Novartis Oncology, where he led the development and global launch of the first approved cell and gene therapy in the U.S. Pascal Touchon currently serves as Chairman of the Board of Atara Biotherapeutics (U.S.), Independent Director at Ipsen, and advisor to Jeito Capital, an investment fund dedicated to biopharmaceutical companies. Pascal holds a Doctorate in Veterinary Medicine from Paul Sabatier University (Toulouse, France) and a MBA from INSEAD (Fontainebleau, France).

A specialist in neuroscience and a graduate in pharmacology, Dr Sabri Markabi has spent more than twenty-five years in international positions in the pharmaceutical industry. In particular, he led the clinical neuroscience department and supervised the development of the ophthalmology unit at Novartis before heading up R&D at the Alcon pharmaceutical company from 2008 to 2015. During his career, Sabri Markabi has taken part in or chaired many corporate governance bodies in private or listed companies. Since 2015, he has advised many companies, specifically regarding their investment strategy and R&D.